Biohaven Pharma's (BHVN) NURTEC ODT Approved In Israel For Acute Treatment Of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "We are excited about this first regulatory approval of NURTEC ODT outside of the United States. Approval of NURTEC ODT in Israel is an important step towards our goal of helping patients worldwide suffering from migraine and the strategic partnership with Medison Pharma will allow us to quickly expand access to NURTEC ODT."

A single quick-dissolving tablet of NURTEC ODT can provide fast pain relief and return patients to normal function within one hour, and deliver sustained efficacy that lasts up to 2 days after a single dose for many patients. NURTEC ODT disperses almost instantly in a person's mouth without the need for water, offering people with migraine a convenient, discreet way to take their medication anytime and anywhere they need it. NURTEC ODT is not indicated for the preventive treatment of migraine. Biohaven partnered with Medison Pharma to pursue regulatory approval of the NURTEC ODT dossier in Israel.

Meir Jakobsohn, Founder and CEO, Medison Pharma commented, "The approval of NURTEC ODT in Israel is the result of our companies' shared efforts and joint commitment to providing access to breakthrough therapies that improve the lives of migraine patients."

You May Also Be Interested In

• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints